BIOGEN INC. Proceeds from (Payments to) Noncontrolling Interests
BIOGEN INC. (BIIB) reported Proceeds from (Payments to) Noncontrolling Interests of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsToMinorityShareholders · last filed 2026-02-06
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for fiscal 2025 was $0.00.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for fiscal 2023 was $12.30M, a 0.81% decline from fiscal 2022.
- BIOGEN INC. proceeds from (payments to) noncontrolling interests for fiscal 2022 was $12.40M.
| Period end | Proceeds from (Payments to) Noncontrolling Interests 3 month | Proceeds from (Payments to) Noncontrolling Interests 6 month | Proceeds from (Payments to) Noncontrolling Interests 9 month | Proceeds from (Payments to) Noncontrolling Interests 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-06 | $0.00 10-K · filed 2026-02-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | $8.10M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $8.10M derived: sum of 3 quarters · filed 2026-02-06 | $10.60M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-24 | $8.10M derived: sum of 2 quarters · filed 2026-02-06 | $10.60M derived: sum of 3 quarters · filed 2026-02-06 | $12.10M derived: sum of 4 quarters · filed 2026-02-06 |
| 2023-12-31 | $8.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $10.60M derived: sum of 2 quarters · filed 2026-02-06 | $12.10M derived: sum of 3 quarters · filed 2026-02-06 | $12.30M 10-K · filed 2026-02-06 |
| 2023-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $4.00M derived: sum of 2 quarters · filed 2024-10-30 | $4.20M 10-Q · filed 2024-10-30 | $4.40M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.70M 10-Q · filed 2024-08-01 | $1.90M derived: sum of 3 quarters · filed 2025-02-12 | $2.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-04-24 | $400.00K derived: sum of 2 quarters · filed 2025-02-12 | $500.00K derived: sum of 3 quarters · filed 2025-02-12 | $12.40M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $300.00K derived: sum of 2 quarters · filed 2025-02-12 | $12.20M derived: sum of 3 quarters · filed 2025-02-12 | $12.40M 10-K · filed 2025-02-12 |
| 2022-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $12.00M derived: sum of 2 quarters · filed 2023-11-08 | $12.20M 10-Q · filed 2023-11-08 | $12.60M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $11.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $12.10M 10-Q · filed 2023-07-25 | $12.50M derived: sum of 3 quarters · filed 2024-02-14 | $12.50M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $200.00K 10-Q · filed 2023-04-25 | $600.00K derived: sum of 2 quarters · filed 2024-02-14 | $600.00K derived: sum of 3 quarters · filed 2024-02-14 | -$94.20M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $400.00K derived: sum of 2 quarters · filed 2024-02-14 | -$94.40M derived: sum of 3 quarters · filed 2024-02-14 | -$94.40M 10-K · filed 2024-02-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$94.80M derived: sum of 2 quarters · filed 2022-10-25 | -$94.80M 10-Q · filed 2022-10-25 | |
| 2021-06-30 | -$94.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | -$94.80M 10-Q · filed 2022-07-20 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | -$71.00M 10-K · filed 2023-02-15 | |||
| 2019-12-31 | $4.30M 10-K · filed 2022-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |